Drug Search Results
More Filters [+]

Glycopyrronium

Alternative Names: glycopyrronium, seebri, drm-04, drm04, drm 04, qbrexza, qva-149, qva149, qva 149, wo-3970, wo3970, wo 3970, glycopyrroniumbromid
Latest Update: 2024-05-30
Latest Update Note: Clinical Trial Update

Product Description

Glycopyrronium (Qbrexza) topical wipes are labeled for the treatment of hyperhidrosis. Glycopyrronium wipes contain a topically-dosed anticholinergic. When applied to the axillae, they reduce sweating in patients nine years and older with hyperhidrosis (Sourced from: https://www.aafp.org/afp/2019/0915/p372.html)

Mechanisms of Action: M1 Antagonist,M2 Antagonist,M3 Antagonist,M4 Antagonist,M5 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Chronic Obstructive Pulmonary Disease | Hyperhidrosis

Known Adverse Events: Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Headache | Pain Unspecified | Erythema | Pruritus | Keratoconjunctivitis Sicca | Mydriasis | Constipation

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Glycopyrronium

Countries in Clinic: Argentina, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Finland, Germany, Guatemala, Hungary, India, Israel, Japan, Korea, Malaysia, Mexico, Netherlands, Philippines, Poland, Puerto Rico, Romania, South Africa, Spain, Thailand, Turkey, United Kingdom, United States, Vietnam

Active Clinical Trial Count: 22

Highest Development Phases

Phase 3: Asthma|Asthma, Allergic|Chronic Obstructive Pulmonary Disease|Hyperhidrosis|Other

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

D5985C00002

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-09-05

74%

D5985C00002

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-09-05

74%

D5985C00002

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-09-05

74%

ATHLOS

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-08-24

74%

ATHLOS

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-08-24

74%

ATHLOS

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-08-24

74%

CQVM149C2201

P2

Recruiting

Asthma

2025-06-10

35%

Recent News Events